摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2-二氢-3H-吡唑并[4,3-b]吡啶-3-酮 | 51617-92-6

中文名称
1,2-二氢-3H-吡唑并[4,3-b]吡啶-3-酮
中文别名
1H-吡唑并[4,3-B]吡啶-3(2H)-酮
英文名称
1,2-dihydro-pyrazolo[4,3-b]pyridin-3-one
英文别名
pyrazolo[4,3-b]pyridine-3(2H)-one;1H-Pyrazol<4,3-b>pyridin-3(2H)-on;Pyrazolo<4,3-b>pyridin-3(2H)-on;1H-Pyrazolo[4,3-b]pyridin-3(2H)-one;1,2-dihydropyrazolo[4,3-b]pyridin-3-one
1,2-二氢-3H-吡唑并[4,3-b]吡啶-3-酮化学式
CAS
51617-92-6
化学式
C6H5N3O
mdl
——
分子量
135.125
InChiKey
XBVTWEMNKKHPEH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    247-248 °C (decomp)
  • 沸点:
    225.8±9.0 °C(Predicted)
  • 密度:
    1.346±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    54
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:46869928371b9fd87ae1e04d2b5cf038
查看

反应信息

  • 作为反应物:
    描述:
    1-甲基苯唑1,2-二氢-3H-吡唑并[4,3-b]吡啶-3-酮 以afforded the desired amine as a yellow solid in 84.8% yield的产率得到3-hydroxy-1-(o-methylaminobenzoyl)-1H-pyrazolo[4,3-b]pyridine
    参考文献:
    名称:
    1-(Aminobenzoyl)-1H-indazol-3-ols
    摘要:
    制备了Aminobenzoyl-1H-indazol-3-ols,它们在调节免疫和控制温血动物的炎症方面很有用。
    公开号:
    US04537966A1
  • 作为产物:
    参考文献:
    名称:
    Evaluation and synthesis of amino-hydroxy isoxazoles and pyrazoles as potential glycine agonists
    摘要:
    Except for structurally similar small amino acids, such as alanine, beta-alanine, and serine, compounds acting as glycine-receptor agonists are an unknown class of pharmacological agents. To investigate the potential of small, substituted heterocycles to act as glycine agonists, we have evaluated the similarities between glycine and a series of hydroxy- and amino-substituted pyrazoles and isoxazoles through complementary molecular modeling techniques. Using a "scorecard approach" to determine the overall similarity of projected agonist structures to glycine, we prioritized synthesis and subsequently prepared several novel derivatives. The biological activity of these compounds was compared to that of glycine by using a [3H]strychnine-mediated glycine receptor binding assay. Despite the close similarity in the calculated parameters when compared to glycine, no significant receptor-binding activity was observed for the targeted analogues. These results illustrate the structurally exacting nature of the glycine receptor.
    DOI:
    10.1021/jm00129a016
点击查看最新优质反应信息

文献信息

  • THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS
    申请人:Gupta Varsha
    公开号:US20120095016A1
    公开(公告)日:2012-04-19
    The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA A receptor and negatively modulating the α5 subtype of GABA A , and use of the compound of formula I in the manufacture of a medicament for the treatment of GABA A receptor associated disorders. The invention further provides a method of modulation of one or more GABA A subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).
    这项发明提供了一种新颖的化学系列,其化学式为I,以及利用该化合物结合到GABA A 受体的苯二氮卓位点并负性调节GABA A 的α5亚型的方法,以及利用化合物I的制备药物治疗GABA A 受体相关疾病的方法。该发明还提供了一种在动物体内调节一个或多个GABA A 亚型的方法,包括向动物体内施用化合物I的有效量。
  • [EN] SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLES BICYCLIQUES SUBSTITUÉS CONDENSÉS EN 6,5
    申请人:EPIZYME INC
    公开号:WO2014144747A1
    公开(公告)日:2014-09-18
    The present invention relates to azole bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    本发明涉及唑类双环杂环芳基化合物。本发明还涉及含有这些化合物的药物组合物,以及通过向需要的受试者投与这些化合物和药物组合物来治疗癌症的方法。本发明还涉及利用这些化合物进行研究或其他非治疗目的的用途。
  • [EN] 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLES BICYCLIQUES 1,4-PYRIDONE
    申请人:EPIZYME INC
    公开号:WO2014100665A1
    公开(公告)日:2014-06-26
    The present invention relates to 1,4-pyridone bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    本发明涉及1,4-吡啶酮双环杂环芳基化合物。本发明还涉及含有这些化合物的药物组合物,以及通过向需要的受试者投予这些化合物和药物组合物来治疗癌症的方法。本发明还涉及利用这些化合物进行研究或其他非治疗目的的用途。
  • [EN] MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES<br/>[FR] INHIBITEURS MACROCYCLIQUES DE PEPTIDYLARGININE DÉIMINASES
    申请人:GILEAD SCIENCES INC
    公开号:WO2021222353A1
    公开(公告)日:2021-11-04
    The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    本公开涉及用于治疗与肽精酸脱亚酶(PADs)相关的疾病的新化合物,例如肽精酸脱亚酶类型4(PAD4)。本公开还涉及用于制备这些化合物的过程和中间体,使用这些化合物的方法以及包含所述化合物的药物组合物。
  • [EN] SUBSTITUTED BENZENE COMPOUNDS<br/>[FR] COMPOSÉS DE BENZÈNE SUBSTITUÉS
    申请人:EPIZYME INC
    公开号:WO2015010049A1
    公开(公告)日:2015-01-22
    The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    本发明涉及取代苯化合物。本发明还涉及含有这些化合物的药物组合物以及通过向需要的受试者投予这些化合物和药物组合物来治疗癌症的方法。本发明还涉及利用这些化合物进行研究或其他非治疗目的的用途。
查看更多

同类化合物

西卡唑酯 维利西呱 盐酸依他唑酯 月桂41-2272 月桂-41-8543 异丁司特 吡唑并[5,1-f]吡啶-6-甲醛 吡唑并[1,5-a]吡啶-7-羧酸 吡唑并[1,5-a]吡啶-7-甲醇 吡唑并[1,5-a]吡啶-7-甲胺 吡唑并[1,5-a]吡啶-5-醇 吡唑并[1,5-a]吡啶-5-胺 吡唑并[1,5-a]吡啶-5-羧醛 吡唑并[1,5-a]吡啶-5-羧酸 吡唑并[1,5-a]吡啶-5-基甲醇 吡唑并[1,5-a]吡啶-4-醇 吡唑并[1,5-a]吡啶-4-羧酸乙酯 吡唑并[1,5-a]吡啶-4-羧酸 吡唑并[1,5-a]吡啶-4-甲醛 吡唑并[1,5-a]吡啶-3-胺盐酸盐 吡唑并[1,5-a]吡啶-3-胺 吡唑并[1,5-a]吡啶-3-羧酸甲酯 吡唑并[1,5-a]吡啶-3-羧酸 吡唑并[1,5-a]吡啶-3-甲醛 吡唑并[1,5-a]吡啶-3-甲酰胺 吡唑并[1,5-a]吡啶-3-甲胺 吡唑并[1,5-a]吡啶-3-基甲醇 吡唑并[1,5-a]吡啶-3-基乙腈 吡唑并[1,5-a]吡啶-3,7-二醇 吡唑并[1,5-a]吡啶-3,7-二胺 吡唑并[1,5-a]吡啶-3,6-二胺 吡唑并[1,5-a]吡啶-3,5-二胺 吡唑并[1,5-a]吡啶-3,4-二胺 吡唑并[1,5-a]吡啶-2-羧醛 吡唑并[1,5-a]吡啶-2-碳酰肼 吡唑并[1,5-a]吡啶-2-甲醇 吡唑并[1,5-a]吡啶-2-甲酸甲酯 吡唑并[1,5-a]吡啶-2-甲酸 吡唑并[1,5-a]吡啶-2-甲胺 吡唑并[1,5-a]吡啶-2,3-二胺 吡唑并[1,5-a]吡啶-2,3-二甲酸二甲酯 吡唑并[1,5-a]吡啶-2,3-二甲酸二乙酯 吡唑并[1,5-a]吡啶-2(1H)-酮 吡唑并[1,5-a]吡啶 吡唑并[1,5-A〕吡啶-3,5-二羧酸-3-乙基 吡唑并[1,5-A]吡啶-7-甲酰胺 吡唑并[1,5-A]吡啶-7-甲腈 吡唑并[1,5-A]吡啶-5-甲腈 吡唑并[1,5-A]吡啶-3-硼酸 吡唑并[1,5-A]吡啶-3-硫代甲酰胺